By Sharnita Midgett
The goal of detecting Alzheimer’s disease earlier and more accurately in patients with cognitive symptoms has led to the development of new diagnostic tools. One tool is the use of spinal taps, which provide physicians with samples of cerebrospinal fluid (CSF) that are analyzed for levels of proteins associated with Alzheimer’s disease.
In a recent U.S. News & World Report article, PMC Co-Director Jason Karlawish, MD, discussed how Alzheimer’s disease is being redefined as a biological disease, with three biomarkers: amyloid plaques, tau tangles and deterioration of the nervous system.
“It holds promise for a more accurate diagnosis for the subset of people who have those biomarkers,” he told U.S. News & World Report. “It holds great promise for the development of treatments that can target those biomarkers.”